Fusion polypeptides that inhibit exocytosis: Fusing aptamer and cell-penetrating peptide technologies and pharmacologies

Molecular Pharmacology

Volumn 67, Issue 4, 2005, Pages 980-982

  Eiden, Lee E ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; HYBRID PROTEIN; OLIGOPEPTIDE; PENETRATIN; POLYPEPTIDE; PROTEIN VP22; SNARE PROTEIN;

CELL CULTURE; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; DRUG PENETRATION; EXOCYTOSIS; MEMBRANE TRANSPORT; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; EXOCYTOSIS; GENE PRODUCTS, TAT; HUMANS; MOLECULAR SEQUENCE DATA; N-ETHYLMALEIMIDE-SENSITIVE PROTEINS; PEPTIDE FRAGMENTS; RECOMBINANT FUSION PROTEINS; VESICULAR TRANSPORT PROTEINS;

EID: 15744397969     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.105.011429     Document Type: Review

References (19)

1. Brody EN and Gold L (2000) Aptamers as therapeutic and diagnostic agents. J Biotechnol 74:5-13.
2. Bruns D and Jahn R (2002) Molecular determinants of exocytosis. Pflueg Arch Eur J Physiol 443:333-338.
3. Derossi D, Joliot AH, Chassaing G, and Prochaintz A (1994) The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 269:10444-10450.
4. Eiden LE (2003) Signaling during exocytosis, in Handbook of Cell Signaling (Bradshaw R and Dennis E eds) pp 375-392, Academic Press, New York.
5. Frankel AD and Pabo CO (1988) Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55:1189-1193.
6. Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, Ueda K, and Sugiura Y (2001) Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 276: 5836-5840.
7. Gallouzi I-E and Steitz JA (2001) Delineation of mRNA export pathways by the use of cell-permeable peptides. Science (Wash DC) 294:1895-1901.
8. Gershoni JM and Aronheim A (1988) Molecular decoys: ligand-binding recombinant proteins protect mice from curaremimetic neurotoxins. Proc Natl Acad Sci USA 85:4087-4089.
9. Geyer CR and Brent R (2000) Selection of genetic agents from random peptide aptamer expression libraries. Methods Enzymol 328:171-208.
10. Green I, Christison R, Voyce CJ, Bundell KR, and Lindsay MA (2003) Protein transduction domains: are they delivering? Trends Pharmacol Sci 24:213-215.
11. Hertting G and Meyer DK (1974) Effect of converting enzyme blockade on isoprenaline- and angiotensin I-induced drinking. Br J Pharmacol 52:381-386.
12. Jahn R and Südhof TC (1999) Membrane fusion and exocytosis. Annu Rev Biochem 68:863-911.
13. Juliano RL, Astriab-Fisher A, and Falke D (2001) Macromolecular therapeutics: emerging strategies for drug discovery in the postgenome era. Mol Intern 1:40-53.
14. Lifson JD, Hwang KM, Nara PL, Fraser B, Padgett M, Dunlop NM, and Eiden LE (1988) Synthetic CD4 peptide derivatives that inhibit HIV infection and cytopathicity. Science (Wash DC) 241:712-716.
15. Lin RC and Scheller RH (2000) Mechanisms of synaptic vesicle exocytosis. Annu Rev Cell Dev Biol 18:19-49.
16. Matsushita K, Morrell CN, and Lowenstein CJ (2005) A novel class of fusion polypeptides inhibits exocytosis. Mol Pharmacol 67:1137-1144.
17. O'Brian CA, Ward NE, Liskamp RM, de Bont DB, and van Boom JH (1990) N-myristyl-Lys-Arg-Thr-Leu-Arg: a novel protein kinase C inhibitor. Biochem Pharmacol 39:49-57.
18. Schwarze SR and Dowdy SF (2000) In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol Sci 21:45-48.
19. Trehin R and Merkle HP (2004) Chances and pitfalls of cell penetrating peptides for cellular drug delivery. Eur J Pharm Biopharm 58:209-223.